PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of arsMary Ann Liebert, Inc.Mary Ann Liebert, Inc.JournalsSearchAlerts
Antioxidants & Redox Signaling
 
Antioxid Redox Signal. 2011 June 15; 14(12): 2385–2397.
PMCID: PMC3096517

Astrocytic Redox Remodeling by Amyloid Beta Peptide

Abstract

Astrocytes are critical for neuronal redox homeostasis providing them with cysteine needed for glutathione synthesis. In this study, we demonstrate that the astrocytic redox response signature provoked by amyloid beta (Aβ) is distinct from that of a general oxidant (tertiary-butylhydroperoxide [t-BuOOH]). Acute Aβ treatment increased cystathionine β-synthase (CBS) levels and enhanced transsulfuration flux in contrast to repeated Aβ exposure, which decreased CBS and catalase protein levels. Although t-BuOOH also increased transsulfuration flux, CBS levels were unaffected. The net effect of Aβ treatment was an oxidative shift in the intracellular glutathione/glutathione disulfide redox potential in contrast to a reductive shift in response to peroxide. In the extracellular compartment, Aβ, but not t-BuOOH, enhanced cystine uptake and cysteine accumulation, and resulted in remodeling of the extracellular cysteine/cystine redox potential in the reductive direction. The redox changes elicited by Aβ but not peroxide were associated with enhanced DNA synthesis. CBS activity and protein levels tended to be lower in cerebellum from patients with Alzheimer's disease than in age-matched controls. Our study suggests that the alterations in astrocytic redox status could compromise the neuroprotective potential of astrocytes and may be a potential new target for therapeutic intervention in Alzheimer's disease. Antioxid. Redox Signal. 14, 2385–2397.

Introduction

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by extracellular deposition of amyloid beta (Aβ) in senile plaques and intracellular formation of neurofibrillary tangles leading to synaptic loss, neuronal death, and progressive cognitive decline (32). Aβ is a 40–42-amino acid-long peptide derived from amyloid precursor protein. The hydrophobic sequence extending from residues 25–35 in the Aβ peptide are responsible for its aggregation and its neurotoxicity (38).

Astrocytes extend between the neuronal and vascular networks and play critical roles in neurotransmitter, amino acid, energy, and volume homeostasis in brain. Astrocytes also support neuronal redox functions by providing cysteine (15), needed for glutathione (GSH) synthesis. Although the neurotoxicity of Aβ is known to be mediated in part by oxidative stress and reduced antioxidant capacity (12), the effects of Aβ on astrocytic redox metabolism are poorly characterized, despite the key role played by these glial cells in neuronal redox homeostasis under normoxic (8, 14) and stress conditions (15). Aβ activates astroglial cells, stimulating reactive oxygen species (ROS) production, which in turn causes hyperoxidation of plasma membrane proteins and lipids, impaired glutamate clearance with consequent excitotoxicity, and disruption of the mitochondrial membrane potential (3, 12).

Cysteine limits synthesis of GSH, a major intracellular antioxidant. Cysteine can be synthesized via the transsulfuration pathway, imported into cells by a specific transporter, ASC, or derived from cystine imported by the xc- transporter (Fig. 1a). Cystathionine β-synthase (CBS) catalyzes the rate-limiting step in the transsulfuration pathway (9). Faced with oxidative stress conditions depleting the GSH pool, astrocytes mount an autocorrective response by activating the transsulfuration pathway and GSH biosynthesis (Fig. 1b) (47). Mature neurons lack an efficient system for cystine uptake and rely instead on astrocytes for provision of cysteine, which is produced from secreted GSH (Fig. 1a) (14). GSH metabolism is critically interlinked to glutamate-based neurotransmission and ion homeostasis via two transporters, xC- and XAG-, and the Na+/K+ ATPase (Fig. 1a). Aberrations at this metabolic nexus are associated with AD (26, 29). Using indirect methods for assessing GSH, two laboratories have reported the effect of Aβ 25–35 on intracellular GSH. However, their results are contradictory. Abramov et al. (2) used monochlorobimane to image GSH and reported an ~50% decrease in intracellular GSH levels after 24 h of Aβ treatment. In contrast, Allaman et al. (5), using the dithionitrobenzoic acid assay, reported an ~300% increase in extracellular GSH with no change in intracellular GSH levels after 48 h of Aβ treatment. The mechanism of GSH extrusion and modulation of its concentration by Aβ were not investigated.

FIG. 1.
The effects of specific versus general oxidants on the astrocytic thiol-based redox metabolism. (a) Pathway for thiol-based redox metabolism. PPG, SAS, AβH, Aza, ACV, and MK-571 are inhibitors of γ-cystathionase, γ-glutamylcysteinyl ...

In this study, we have examined the effects of acute and repeated Aβ treatment on astrocytic GSH biosynthesis, redox potential, and the transsulfuration pathway and compared them with the effects elicited by tertiary-butylhydroperoxide (t-BuOOH) treatment. We find that both short and repeated Aβ treatment induce a reductive redox potential in the extracellular milieu but an oxidative shift in the intracellular compartment. Acute Aβ treatment increased CBS levels and enhanced transsulfuration flux in contrast to repeated Aβ exposure, which decreased CBS and catalase protein levels. Further, Aβ orchestrates an intracellular response, which is mechanistically distinct from that of a nonspecific oxidant, including changes in CBS and catalase protein levels and DNA synthesis that are not seen with t-BuOOH treatment. CBS levels and activity appear to be lower in the cerebellum of AD brains than in age-matched controls, indicating a pathological relevance for the ex vivo observation. These results reveal the importance of identifying disease-specific redox signatures, which could have the potential for development of metabolism-based disease-modifying therapeutic approaches.

Materials and Methods

Biological samples

AD brain and age-matched control samples were from the Michigan Alzheimer's Disease Research Center Brain Bank. AD samples were derived from clinically well-characterized individuals participating in a prospective brain collection program. At death, one hemisphere was cut into 1–1.5 cm coronal slabs and frozen rapidly over liquid N2 vapor and stored in heat-sealed freezer bags at −80°C until use. The other hemisphere was fixed in 10% neutral buffered formalin and used for neuropathologic analysis. All specimens are reviewed by the same neuropathologist and diagnosis established by the Reagan-NIA criteria (13). Age, gender, and postmortem delay-matched control specimens were derived from individuals with no clinical history of neurologic disease and normal neuropathologic examinations. Slabs were warmed to −20°C and blocs of frontal cortex and cerebellum were prepared. The University of Michigan's Committee on Use and Care of Animals approved the protocol used in this study for handling animals.

Isolation and preparation of murine primary cells

Primary murine cortical astrocytes cultures were prepared from 1- to 2-day-old Balb/c pups as described previously (20, 21). At the end of the third passage, cells were seeded in 6-well (2×106 cells/well/2 ml), 24-well (5×105 cells/well/ml), or 48-well plates (5×104 cells/well/0.4 ml), or a 8-well chamber slide (1×105 cells/well/0.4 ml), depending on the experiment, and incubated for a week (with half the medium being changed every third day). The purity of astrocytes was determined as described previously (21) and was ≥93%.

Dissociated neurons were prepared as described previously from embryonic day 16 (E16) to E18 mice and cultured (1×105 cells/well/0.5 ml) in neurobasal media containing B27 (1×) supplement, 2 mM L-glutamine and penicillin–streptomycin (100 units/ml and 100 μg/ml final concentration, respectively) on laminin (Invitrogen) and poly-D-lysine (Sigma)-coated glass cover slips (12 mm; Bellco Glass) in 24-well plates (20, 21). The purity of neurons was assessed by staining with antibody to anti-β III tubulin (TUJ1) and found to be >95% as observed microscopically.

Aggregation of Aβ peptide

The lyophilized form of the triflouroacetate salt of the Aβ peptide (25–35, or 1–42 Bachem) was aggregated as described previously (37). Briefly, Aβ was dissolved in sterile double-distilled water as a 2 mM stock solution, incubated for 8 days at 37°C, and stored in aliquots at −80°C. Soluble Aβ (2 mM) was prepared by dissolving lyophilized peptide in 1% dimethyl sulfoxide and stored immediately at −80°C.

Aβ treatment of primary astrocyte cultures

At the start of experiments, astrocytes were replenished with fresh astrocyte media (Dulbecco's modified Eagle's medium/F12+2 mM L-glutamine+10% heat inactivated fetal bovine serum+penicillin-streptomycin (100 units/ml and 100 μg/ml final concentration, respectively). For the acute treatment, a single bolus of 200 μM t-BuOOH or 50 μM Aβ (25–35) or 10 μM Aβ (1–42) was added and incubation was continued for the desired times (Fig. 1c). For the repeated treatment model, astrocytes were stimulated with 50 μM Aβ (25–35) or 10 μM Aβ (1–42) repeatedly (3 bolus treatments, once every 72 h), and experimental analysis was started after the third Aβ treatment (Fig. 1c). Cell death was observed in <10% of astrocytes after acute or repeated Aβ treatment as monitored by the PI-AV labeling kit (data not shown; BioVision) and TUNEL assay kit (Roche) according to the vendor's protocol. Sulfasalazine (SAS, 500 μM), MK571 (100 μM), acivicin (400 μM), azaserine (500 μM), and aspartate-β-hydroxamate (400 μM) (Sigma) when used were added in a single bolus at the start of the acute Aβ treatment or the third exposure to repeated Aβ treatment regimen. The effect of Aβ dose on astrocyte viability and metabolite levels was determined after a single bolus treatment with 1, 10, or 50 μM Aβ (acute model) or with the same Aβ concentrations but administered using the repeated treatment regimen described above. To study the response of the transsulfuration pathway during acute and repeated stimulation with either t-BuOOH or Aβ, cells were incubated with L-(35S)-methionine (Perkin Elmer) to a final concentration of 2 μCi/ml in the presence or absence of 2.5 mM propargylglycine for 6 or 12 h. At the indicated time points, culture supernatants were removed and used immediately for H2O2 analysis or stored frozen at −80°C until used for determination of extracellular thiols. Cells were harvested and frozen at −80°C until further use.

CBS analysis in the human brain samples

Frozen brain tissue (~300 mg) was pulverized in liquid N2 and CBS activity and protein expression in the postmortem brain samples of patients with AD and age-related normal subjects were analyzed as described previously (46).

Metabolite analyses

Extracellular thiols (cystine, cysteine, and GSH) in cell culture medium were quantified in metaphosphoric acid-fixed protein-free supernatant as described previously (20, 35). Intracellular GSH and incorporation of (35S) from methionine into GSH was quantified as described previously (20, 35). The results were normalized to the protein concentration in each sample.

(3H)-thymidine incorporation assay

Astrocytes (5×104/well) were seeded at ~50%–70% confluency in 48-well plates at day 0. After stimulation with Aβ (2535) or t-BuOOH for 2 h, cells were incubated with (3H)-thymidine (1 μCi/ml; Perkin Elmer) for a further ~24 h at 37°C. Cells were washed twice with phosphate-buffered saline (PBS) and dissolved in 100 μl NaOH (0.2 M). The samples were mixed with scintillation cocktail and radioactivity incorporation was measured.

Western blot analysis

Astrocytes with the indicated treatments and at the desired time points were harvested and lysed on ice as described previously (19). Antibodies against CBS, catalase, superoxide dismutase 1 (SOD1) (Abcam), actin (Sigma), and xCT, the catalytic subunit of xC− (Novus Biological), were used to monitor expression of the respective protein antigens and detected using the Dura chemiluminescent horseradish peroxidase system (Pierce).

Determination of extracellular H2O2 and intracellular ROS

Astrocytes were treated with a single bolus of the 25–35 Aβ peptide for 3 and 24 h acutely or repeatedly as described above. To check the effect of antioxidant on ROS production, astrocytes were pre-treated or not with 1 mM N-acetyl cysteine (NAC) for 24 h and then incubated with Aβ 25–35 (50 μM) or 1–42 (10 μM) for 3 h. Alternatively, astrocytes were transfected with catalase-His-V5-expressing pCDNA3.1 (a generous gift from Brent Carter, University of Iowa) or the empty pCDNA3.1 plasmid using TransIT-2020 reagent (Mirus) as per the manufacturer's protocol. After 24 h post transfection, cells were incubated with Aβ 25–35 (50 μM) or 1–42 (10 μM) in fresh media for 3 h. After Aβ stimulation, the astrocyte conditioned medium was saved for extracellular H2O2 determination, whereas the cells were used for intracellular ROS detection using the Image-iT Live Green ROS Detection Kit as per the manufacturer's protocol (Invitrogen). Briefly, cells were washed twice with Ca2+- and Mg2+-free Hank's balanced salt solution (HBSS), followed by incubation with 5-(and-6)-carboxy-2′,7′-dichlorodihydrofluorescein diacetate (Invitrogen) at a final concentration of 5 μM for 30 min at 37°C. Cells were washed once with HBSS and incubated with Hoechst 33342 nuclei stain (1:200 dilution, excitation 365 nm, emission 480 nm; Invitrogen) for 10 min at 37°C to ensure equal cell numbers. Cells were washed three times with HBSS followed by lysing using the lysis buffer. An aliquot of lysate (100 μl each) was transferred to a fluorimetric plate, the fluorescence excitation/emission maxima were recorded at 495/529 nm and the results expressed as F529/F480 nm. The concentration of H2O2 in the conditioned media was measured using the Amplex Red reagent kit as per the manufacturer's protocol (Molecular Probe). Conditioned media (100 μl) in a 96-well fluorimetric plate was mixed with 10 μM Amplex red reagent and 1 U/ml horseradish peroxidase at a 1:1 ratio and incubated for 30 min at room temperature. A standard curve was generated with known concentrations (50 nM to 10 μM) of H2O2. The amount of resorufin produced by Amplex Red oxidation was determined fluorimetrically (excitation: 544 nm, emission: 590 nm). Background fluorescence was determined for the medium control and subtracted from each value and results were expressed as the concentration of H2O2 in the medium.

Analysis of apoptosis

The terminal deoxynucleotidyl transferase-dUTP nick end labeling (TUNEL) assay (Roche Diagnostics) was employed as previously described (20). Briefly, astrocytes were cultured in 24-well plates and treated acutely or repeatedly with 50 μM (2535) or 10 μM (142) Aβ as described above. After incubation, 500 μl of each conditioned media was transferred on to neuronal monolayers in 250 μl neuronal media in the presence or absence of 50 μM Aβ (2535). Neurons were incubated for another 12–14 h followed by labeling with the TUNEL stain. To check the effect of Aβ or t-BuOOH on viability, astrocytes were treated with different concentrations of Aβ (2535) peptide (1, 10, 50 μM) or t-BuOOH (200, 400, 800 μM) for 12–14 h followed by labeling with the TUNEL stain. Nuclei were observed with Hoechst stain (1:200 dilution, excitation 365 nm, emission 480 nm; Invitrogen) and quantitative analysis was performed by counting >2000 cells as described previously (20).

Analysis of mitochondrial activity

To check the effect of Aβ on astrocytic mitochondrial activity, the 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assay was employed as previously described (47). In brief, astrocytes (1×106/well) in 24-well plates were treated with different concentration of Aβ (2535) acutely or repeatedly. After stimulation for ~20 h, cells were washed with PBS and incubated with MTT dye (0.5 mg/ml) for 2 h at 37°C, followed by washing with PBS. Cells were dissolved in dimethyl sulfoxide. Optical density was measured at 553 nm and the background was corrected after reading the absorbance at 650 nm.

Statistical analyses

The significance of the differences in data between control and experimental groups was determined by one-way analysis of variance followed by post-test Bonferroni adjustment. Students t-test (paired, two-tailed) was also performed for comparison with the analysis of variance test. p<0.05 was considered to be statistically significant.

Results

Protracted increase in astrocytic ROS production by Aβ

Since the kinetics of Aβ-induced ROS production by astrocytes and microglia have previously been monitored only on a short time scale (3, 24), we examined the intracellular ROS and extracellular H2O2 levels on a longer time scale during which metabolic changes are typically observed (Fig. 2). Acute Aβ treatment was reported to induce an ~2-fold increase in ROS levels 30 min after exposure (3). We found similarly increased ROS levels even at 3 h after acute Aβ (2535) exposure, but the levels declined to control values after 24 h (Fig. 2a). In contrast, intracellular ROS levels were ~3- and ~5-fold higher at the same times after the last Aβ (2535) addition in the repeated treatment regimen (Fig. 2a). Since ROS are typically short-lived, these results reveal that both acute and repeated Aβ-treatment regimens provoke sustained ROS production spanning several hours. ROS production is paralleled by increased extracellular H2O2, with the kinetics of H2O2 increase and dissipation varying with the treatment regimen. Extracellular H2O2 levels were ~4-fold higher after 24 h of acute and ~2-fold higher after 24 h of repeated Aβ treatment (Fig. 2b). The longer Aβ (142) peptide increased intracellular ROS by ~50% and extracellular H2O2 by ~65% after 3 h of treatment (Fig. 2c, d). Addition of the antioxidant, NAC, a cysteine precursor, or over expression of catalase, a peroxide scavenger, decreased Aβ-mediated over production of ROS (Fig. 2c, e) and H2O2 (Fig. 2d, f). When freshly prepared 50 μM Aβ (2535) was used instead of the aggregated form, it failed to induce over production of intracellular ROS and extracellular H2O2 (Fig. 2g, h). Catalase, SOD, and GSH peroxidase are major antioxidant enzymes in mammalian cells that clear ROS. We checked the expression levels of two of these antioxidant enzymes and found that repeated but not acute Aβ (2535) treatment decreased steady-state levels of catalase, whereas Cu/Zn SOD1 was unchanged by either treatment (Fig. 2i). In contrast, neither acute nor chronic t-BuOOH treatment affected catalase or SOD1 expression levels (Fig. 2i). Since the magnitude of ROS stimulation seen with Aβ (2535) and (142) was similar, and NAC similarly abrogated ROS accumulation, further experiments were conducted with the shorter peptide.

FIG. 2.
Antioxidant (NAC or catalase) treatment abrogates Aβ-mediated ROS generation in astrocytes. (a, b) Astrocytes (AG) were incubated with none (white bar), 50 μM Aβ 25–35 acute (gray bar), or repeated (black bar), ...

Differential responses in transsulfuration and GSH synthesis pathways to acute versus repeated Aβ treatment

One mechanism by which human astrocytes respond to oxidative stress induced by t-BuOOH is by increasing flux through the transsulfuration pathway (47), which furnishes cysteine and results in increased GSH synthesis. In murine astrocytes, acute t-BuOOH or acute Aβ (2535) stimulation also induced GSH synthesis at levels that were comparable at 6 and 12 h (Fig. 3a). When freshly prepared 50 μM soluble Aβ (2535) was used, no change in GSH levels was observed at 6 h (Fig. 3b). An ~50% increase in radiolabel incorporation from (35S)-methionine to GSH was observed in 6 h upon acute t-BuOOH or acute Aβ stimulation (Fig. 3c) that was inhibited ~2-fold by propargylglycine, a suicide inhibitor of γ-cystathionase, the second enzyme in the transsulfuration pathway (Fig. 1a), demonstrating the role of this pathway in the astrocytic response to acute oxidative challenge. In contrast, GSH levels were unchanged by repeated treatment with either t-BuOOH or Aβ (2535) after 6 h and diminished ~20% with Aβ after 12 h (Fig. 3a). Repeated Aβ treatment (2535) resulted in an ~2-fold decrease in the transsulfuration flux (Fig. 3d). Glutathione disulfide (GSSG) levels were ~3-fold higher in response to t-BuOOH at 6 h but normalized to control levels at 12 h (Fig. 3e). In contrast, acute Aβ treatment (2535) caused a slower increase in GSSG levels, which were 20% higher at 6 h and twofold higher at 12 h in comparison to the untreated control. An effect on the GSSG concentration was not observed with repeated t-BuOOH and Aβ treatment. As a result of the varied responses in the GSH and GSSG pool with different treatments, the GSH:GSSG ratio, an indicator of the intracellular redox poise, initially decreased in response to acute (~30%) and repeated (~50%) t-BuOOH treatment at 6 h but subsequently overshot control values at 12 h (Fig. 3f). In contrast, both acute and repeated Aβ treatments resulted in an oxidative shift in the intracellular GSH/GSSG ratio.

FIG. 3.
Astrocytes upregulate the transsulfuration pathway during acute treatment with t-BuOOH or Aβ. Astrocytes (AG) were treated with either none (white bar) or acutely with a single bolus of either 200 μM t-BuOOH (gray bar) or 50 μM ...

CBS catalyzes the committing step in the transsulfuration pathway and Western blot analysis revealed that CBS protein levels increase in response to acute treatment with Aβ (2535) but decrease in response to repeated treatment (Fig. 3g). In contrast, neither acute nor repeated t-BuOOH affected CBS levels. Hence, the astrocytic redox responses to Aβ versus an organic peroxide challenge and to acute- versus repeated exposure to Aβ are distinct.

Aβ induces oxidative remodeling of the intracellular GSH/GSSG redox potential

The GSH/GSSG potential is initially slightly oxidized at 6 h in response to acute (−241 mV) and repeated (−244 mV) t-BuOOH treatment compared with control (−247 mV) but subsequently overshoots the control value by appoximately −10 mV at 12 h (Fig. 3h). In contrast, acute Aβ treatment (2535) results in an oxidative shift in the GSH/GSSG potential to −237 mV at 12 h, whereas repeated Aβ treatment elicits the same change within 6 h.

Aβ induces reductive remodeling of the extracellular cysteine/cystine redox potential

The cysteine:cystine ratio is a key determinant of the extracellular redox poise (33). Hence, the kinetics of extracellular cystine consumption and cysteine accumulation were monitored and were strikingly more rapid in the presence of Aβ (2535) than in untreated controls (Fig. 4a, b) and dependent on the dose of Aβ (Fig. 5a, b). Aβ (142) caused similar changes in cysteine and cystine (data not shown). Levels of xCT, the catalytic subunit of the primary cystine transporter, xC-, were not affected by acute Aβ (2535) treatment but were downregulated >4-fold with repeated Aβ treatment (Fig. 4c). Neither acute nor repeated t-BuOOH treatment influenced xCT levels (Fig. 4c) or affected cystine consumption significantly (data not shown). The cysteine/cystine redox couple is important for controlling the redox poise in the extracellular space. The extracellular cysteine/cystine redox potential in untreated cells was estimated to be appoximately −80 mV at 2 h. After 6 h of culture, the redox potential decreased to −90 mV (untreated controls) versus −105 mV (acute Aβ treatment) and −124 mV (repeated Aβ treatment), indicating a more reducing environment (Fig. 4d) and the magnitude of the reductive shift was dependent on the dose of Aβ (Fig. 5c). As expected, t-BuOOH caused cysteine oxidation and the redox potential increased to a more positive value at 2 h but normalized to control values in 6 h (Fig. 4d). Neither acute nor repeated t-BuOOH treatment altered the extracellular GSH concentration, whereas a time-dependent increase in extracellular GSH was observed in response to Aβ treatment (Fig. 4e), which was dependent on the dose of Aβ (Fig. 5d). Thus, the metabolic response both inside and outside the cell to Aβ-induced increase in ROS levels results in reductive remodeling in the extracellular compartment.

FIG. 4.
Changes in the extracellular cysteine/cystine redox potential in response to t-BuOOH or Aβ treatment. Astrocytes were either untreated (circle or while bar) or treated acutely (square or gray bar) or repeatedly (triangle or balck bar) with 50 μM ...
FIG. 5.
Dose dependence of Aβ on the extracellular cysteine/cystine redox couple. Astrocytes were either untreated (white bar), or treated acutely (gray bar) or repeatedly (black bar) with 1, 10, and 50 μM of Aβ (25–35). ...

Aβ induces DNA synthesis

Since a reductive shift in the extracellular potential is usually correlated with cell proliferation, the effect of Aβ (2535) on DNA synthesis was assessed. Like dendritic cells that remodel the extracellular redox potential to support T cell proliferation (49), the astrocytic response to Aβ might similarly stimulate a proliferative glial response. Acute Aβ treatment increased (3H)-thymidine incorporation into DNA by ~50% (Fig. 6) as seen previously (27), while a robust 300% increase was observed with repeated Aβ treatment. In contrast, t-BuOOH decreased (3H)-thymidine incorporation into DNA modestly when applied as a single bolus, whereas repeated t-BuOOH treatment resulted in a 200% decrease (Fig. 6).

FIG. 6.
DNA synthesis is induced by Aβ but not by peroxide. After acute or repeated treatment with Aβ or t-BuOOH, cells were incubated with (3H)-thymidine (1 μCi) for ~24 h at 37°C, before radioactivity ...

Intracellular GSH is source of extracellular cysteine

Extracellular cysteine is derived from the breakdown of secreted GSH via the γ-glutamyl pathway (49). To establish the involvement of this pathway in the astrocytic response to Aβ (2535), we employed pharmacological inhibition at various steps (Fig. 1a). Inhibition of cystine import with SAS, GSH export with MK-571, or extracellular GSH cleavage with acivicin significantly decreased extracellular cysteine accumulation (Fig. 7a). In contrast, inhibition of XAG-, which has a low affinity for cysteine, or inhibition of ASC, the neutral amino acid transporter, did not have a significant effect on extracellular cysteine accumulation. Of these inhibitors, only SAS and to a smaller extent, MK-571, diminished cystine consumption from the medium (Fig. 7b). whereas the decrease in cystine consumption in the presence of SAS is expected, the effect of MK-571 might be indirect, that is, by inhibiting GSH efflux, it inhibits cystine uptake.

FIG. 7.
The γ-glutamyl cycle is a primarily responsible for cysteine release from astrocytes. Astrocytes (AG) were either untreated (white bar), or treated acutely (gray bar) or repeatedly (black bar) with 50 μM Aβ (25–35)±different ...

Aβ does not cause astrocytic apoptosis but decreases mitochondrial activity

Aβ-mediated cellular toxicity and apoptosis are reported in AD (3, 5, 6) and primary neurons are very sensitive to Aβ-induced apoptosis. Astrocytes exposed to 50 μM Aβ (2525) are resistant to apoptosis after exposure to Aβ (2535) as monitored by the TUNEL (Fig. 8a) or Annexin-V (data not shown) assays. In contrast, 800 μM t-BuOOH induced apoptosis in ~80% of the astrocytes but not at 400 μM (not shown) as measured using the TUNEL assay. Interestingly, the MTT assay, a reporter of mitochondrial activity, showed a dose-dependent decrease (~10%–35%) in response to Aβ (2535) treatment, which was concentration dependent (Fig. 8b). In contrast, 200 μM t-BuOOH did not show a significant reduction of MTT (data not shown).

FIG. 8.
Aβ does not cause astrocytic cell death but impairs the mitochondrial activity in a dose-dependent manner. (a) After stimulation with Aβ (50 μM; 25–35) or t-BuOOH (800 μM), the extent of astrocytic ...

Repeated Aβ treatment abrogates the neuroprotective effect of astrocytes

Cysteine enhances GSH synthesis in neurons and is a known neuroprotectant (15). Since Aβ stimulates extracellular cysteine accumulation by astrocytes, the effect of astrocyte-conditioned media on protecting neurons from Aβ-induced apoptosis was examined. For this, astrocytes were stimulated acutely or repeatedly with 50 μM Aβ (2535) or 10 μM Aβ (2535) as described under the Materials and Methods section and after 12–14 h of incubation, conditioned medium was removed and transferred onto neuronal monolayers in the presence or absence of 50 μM Aβ for 12–14 h after which apoptosis was assessed by the TUNEL assay (Fig. 9). Unlike astrocytes that were not found to undergo apoptosis in response to 50 μM Aβ treatment (Fig. 8a), ~50% neuronal cell death was observed. Conditioned medium from untreated or acutely treated astrocyte cultures afforded similarly modest but significant protection of neurons from apoptosis compared with fresh medium (Fig. 9a, b). In contrast, when conditioned medium from astrocyte cultures exposed to repeated Aβ treatment was used, the neuroprotective effect was abrogated (Fig. 9a, b). The effect of astrocyte-conditioned medium from cultures that had received either acute or repeated Aβ treatment regimens on survival of neurons that had not been exposed to Aβ was assessed (Fig. 9c). Conditioned media from either untreated or acutely treated astrocytes (with either Aβ 25–35 or 1–42) did not cause neuronal toxicity. However, conditioned media from astrocytes exposed to the repeated Aβ regimen caused significant neuronal apoptosis (Fig. 9c). Notably, the extent of chronic Aβ 1–42-mediated apoptosis was considerably lower than for Aβ 25–35 (Fig. 9c).

FIG. 9.
Repeated Aβ treatment abrogates the neuroprotective effect of astrocytes. Primary murine cortical neurons were treated (a, b) or untreated (c) with Aβ (50 μM) for ~14 h in the presence of either fresh or ...

Changes in CBS levels and activity in AD brain

Immunohistochemical localization of CBS in adult murine brain reveals weak and diffuse labeling with the exception of the hippocampus and cerebellum, where the labeling is intense (42). Since cerebellar and cortical tissues from AD patients and age-matched controls were more readily available than hippocampal tissue, we compared CBS activity and protein levels in these samples (Fig. 10). Although differences were not observed in the frontal cortex, cerebellum from AD patients tended to exhibit both lower CBS expression (Fig. 10a, b) and activity (Fig. 10c). However, due to high variations and relatively low sample number, the difference did not reach statistical significance. Moreover, differences in CBS protein level and activity between AD and healthy subjects did not correlate with sex, age, and postmortem time of the individual specimens (Supplementary Table S1; Supplementary Data are available online at www.liebertonline.com/ars).

FIG. 10.
CBS activity and protein expression levels are diminished in cerebellum of AD patients. (a) Representative Western blot analysis showing CBS levels in postmortem cerebellum of AD patients and age-matched normal individuals. N and AD denote normal and ...

Discussion

While oxidative stress is a nonspecific hallmark of many neurodegenerative diseases (6), the sequelae of specific redox potential changes in the intra- versus extra-cellular compartments that govern disease-specific signaling and metabolic responses are unknown. Since H2O2 is reported to mediate Aβ toxicity (11), we investigated thiol-based redox responses of astrocytes to Aβ versus the organic peroxide, t-BuOOH, and discovered that they elicit significantly different effects (Fig. 1b).

Cellular functions such as proliferation, differentiation, and death signals are modulated in part by the intracellular and extracellular redox potentials (43). Mammalian cells have multiple redox buffering systems (22). The redox potential of the extracellular compartment is regulated dynamically by intracellular redox metabolism, and, in contrast to the importance of the GSH/GSSG redox couple inside the cell, the cysteine/cystine redox pair is quantitatively the most significant thiol-based redox buffer outside the cell (33). A reductive shift (i.e., to a more negative redox potential value) is associated with cellular proliferation, whereas an oxidative shift correlates with cell death (33). Our results, that is, that Aβ treatment induces a reductive shift, in contrast to a general oxidant, in the extracellular redox potential in astrocytic cultures, suggest that a similar response in the CNS might stimulate proliferation of microglia, exacerbating neuronal degeneration. In fact, inflammation is considered to contribute to neuronal demise in AD (4).

Our study also reveals that the astrocytic redox response to Aβ stimulation is complex and distinct in the intra- versus extra-cellular compartments. Paradoxically, elevated H2O2 levels are observed under conditions where there is a net shift in the extracellular redox potential in the reductive direction in response to Aβ treatment (Figs. 35), emphasizing the importance of analyzing metabolic responses to oxidative stress in the context of the redox milieu in addition to the levels of the individual oxidant species. Ectodomains of membrane proteins are rich in disulfide bonds, and the ~30 mV decrease in redox potential induced by repeated Aβ treatment (Figs. 4 and and5)5) is expected to result in a 10-fold shift in the equilibrium from the disulfide to the dithiol state. The redox state of receptors and transporters influence both their structure and function and the Aβ-induced reductive shift is likely to have pleiotropic consequences on signaling pathways emanating from redox-sensitive membrane protein targets that await elucidation.

An interesting parallel in extracellular reductive remodeling is seen with dendritic cells during activation of T cells and results from increased cystine consumption and extracellular cysteine secretion without enhanced transsulfuration flux (49). The released cysteine is used by naïve T cells, which, like neurons, are unable to efficiently transport cystine. In the CNS, cysteine accumulation, if unchecked, might lead to N-methyl D-aspartate receptor excitoxicity (36). We speculate that the threshold between a neuroprotective versus toxic concentration of cysteine may be crossed if astrocytes are overactivated by repeated Aβ stimulation. As previously shown with dendritic cells, the γ-glutamyl cycle is also the source of extracellular GSH and cysteine in astrocytes (49). Inhibition of the xC- antiporter, the GSH exporter or γ-glutamyltranspeptidase all lead to lower extracellular cysteine accumulation (Fig. 7a). While secretion of extracellular thioredoxin by dendritic cells during T cell activation was proposed to contribute to cysteine accumulation (7), subsequent studies have ruled out a role for thioredoxin in this process (49). Additional redox systems not examined in this study are also likely to contribute to the redox remodeling induced by Aβ, For instance, a Cu-Zn-type extracellular SOD has been shown to delay oxidation of extracellular GSH (45).

The profiles of intracellular redox responses elicited by acute versus repeated exposure to Aβ are also distinct from the corresponding response triggered by t-BuOOH (Fig. 1b). Astrocytes responded to peroxide treatment by a compensatory increase in GSH synthesis, without affecting CBS enzyme level, leading to a net reductive shift in the intracellular GSH/GSSG potential (Fig. 3). Although t-BuOOH treatment does not affect CBS levels, flux through the transsulfuration flux is increased and could result from changes either up- or down-stream of CBS, which remain to be elucidated. The GSH:GSSG ratio is initially diminished in response to acute (~30%) and chronic (~50%) t-BuOOH treatment at 6 h but subsequently overshoots the control values at 12 h (Fig. 3h). In an autocorrective response, cells increase GSH synthesis to counter oxidative stress, leading to more reducing redox potential at 12 h. Cells treated repeatedly with t-BuOOH show a different response, that is, lower GSSG levels (Fig. 3e). The net result, nevertheless, is more reducing conditions.

In contrast, both acute and repeated Aβ treatment resulted in an oxidative shift in the GSH/GSSG redox potential. With acute Aβ treatment, the decline in the redox potential was driven by the time-dependent increase in GSSG levels, whereas with repeated Aβ treatment, the concentration of GSSG increased transiently before returning to control levels (Fig. 3e). However, the concentration of reduced GSH also decreased over time with chronic Aβ treatment, which resulted in a lower redox potential. The difference between the acute versus repeated response to Aβ suggests that metabolic adaptation occurs during prolonged Aβ treatment that results in lowering of the GSSG pool. Since the astrocytic GSH pool also serves as an important cysteine reservoir for supporting neuronal GSH synthesis via secretion and cleavage, the smaller GSH pool size due to extended Aβ exposure could compromise this neuroprotective function of astrocytes.

CBS protein levels were diminished after repeated Aβ but not peroxide treatment (Fig. 3g). A similar trend was observed in cerebellar CBS levels and activity in AD versus control samples, but did not reach statistical significance (Fig. 10). This could have resulted from large inter-individual variations, the relatively small sample size as well as sample heterogeneity, that is, if decreased CBS were restricted to astrocytes in AD, the difference would be underestimated in tissue samples due to the presence of nonastrocytic cells. Since CBS plays an important role both in GSH-linked redox homeostasis (10, 35) and in H2S biogenesis (44), reduced expression of this protein in AD brain if seen might be significant in disease pathology. H2S, which modifies long-term potentiation (1), is reported to be severely depressed in AD brain (17). In addition, levels of S-adenosylmethionine, an allosteric activator (18) and stabilizer (39) of CBS, are decreased in AD brain, but not in idiopathic Parkinson's disease patients, suggesting that the change is not generally correlated with a chronic neurodegenerative disease but may be AD specific (34). Hence, upregulation of CBS expression or its activation or stabilization might represent a specific therapeutic strategy for alleviating redox perturbations associated with AD.

NAC treatment or catalase overexpression abrogated the Aβ-induced ROS generation (Fig. 2). Catalase or SOD overexpression have been shown to decrease ROS levels and rescue neurons from the toxic action of the Aβ peptide (16, 30), consistent with overproduction of ROS contributing to neurotoxicity. Our finding that catalase but not SOD1 levels were diminished after repeated Aβ treatment is consistent with the earlier observation that brain catalase but not SOD activity is decreased in patients with Alzheimer's type dementia (23, 40). Ferritin and catalase are potent suppressors of Aβ toxicity (41). For to be effective against Aβ-induced ROS accumulation, downstream antioxidant enzymes such as catalase and/or GSH peroxidase, which remove H2O2, the product of SOD, need to be also act in concert. A direct effect of Aβ on catalase has been shown, which resulted in deactivation of catalase and increased cellular intracellular H2O2 (25). Although some studies report decreased SOD activity (31, 48), others report either no change (23, 40) or increased SOD activity in AD patients compared with controls (28).

Clearly, the Aβ effects on redox homeostasis are more complex than simply being mediated via peroxide as proposed (11). The aim of the present study was to determine differences, if any in astrocytic responses to a specific (e.g., Aβ) versus a general (e.g., t-BuOOH) oxidant insult. In the present study, we report for the first time, a detailed mechanistic analysis of the redox changes in astrocytes in response to Aβ treatment. Although Aβ treatment stimulates H2O2/ROS production in astrocytes, the intra- and extra-cellular metabolic responses are distinct from those of a nonspecific oxidant, and await full mechanistic elucidation. In summary, our study points to the importance of identifying AD-specific redox markers that might be etiologically important and could serve as potential therapeutic targets.

Supplementary Material

Supplemental data:

Abbreviations Used

amyloid beta
AβH
aspartate-β-hydroxamate
ac
acute
ACV
acivicin
AD
Alzheimer's disease
Aza
azaserine
CBS
cystathionine β-synthase
Cys
cysteine
Cys2
cystine
GSSG
glutathione disulfide
GSH
glutathione
MRP1
multidrug resistance protein 1
MTT
(3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide)
NAC
N-acetyl cysteine
PPG
propargylglycine
ROS
reactive oxygen species
rpt
repeated
SAS
sulfasalazine
SOD
superoxide dismutase
t-BuOOH
tertiary-butylhydroperoxide
TUNEL
terminal deoxynucleotidyl transferase-dUTP nick end labeling

Acknowledgments

This work was supported in part by grants from the National Institutes of Health (DK64959). Support for the Michigan Alzheimer's Disease Research Center (5P50 AG008761) from the National Institutes of Health is gratefully acknowledged. This work utilized the Morphology and Image Analysis Cores of the Michigan Diabetes Research and Training Center funded by NIH5P60 DK20572 from the National Institute of Diabetes & Digestive & Kidney Diseases.

Author Disclosure Statement

No competing financial interests exist.

References

1. Abe K. Kimura H. The possible role of hydrogen sulfide as an endogenous neuromodulator. J Neurosci. 1996;16:1066–1071. [PubMed]
2. Abramov AY. Canevari L. Duchen MR. Changes in intracellular calcium and glutathione in astrocytes as the primary mechanism of amyloid neurotoxicity. J Neurosci. 2003;23:5088–5095. [PubMed]
3. Abramov AY. Canevari L. Duchen MR. Beta-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J Neurosci. 2004;24:565–575. [PubMed]
4. Akiyama H. Barger S. Barnum S. Bradt B. Bauer J. Cole GM. Cooper NR. Eikelenboom P. Emmerling M. Fiebich BL. Finch CE. Frautschy S. Griffin WS. Hampel H. Hull M. Landreth G. Lue L. Mrak R. Mackenzie IR. McGeer PL. O'Banion MK. Pachter J. Pasinetti G. Plata-Salaman C. Rogers J. Rydel R. Shen Y. Streit W. Strohmeyer R. Tooyoma I. Van Muiswinkel FL. Veerhuis R. Walker D. Webster S. Wegrzyniak B. Wenk G. Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383–421. [PubMed]
5. Allaman I. Gavillet M. Belanger M. Laroche T. Viertl D. Lashuel HA. Magistretti PJ. Amyloid-beta aggregates cause alterations of astrocytic metabolic phenotype: impact on neuronal viability. J Neurosci. 2010;30:3326–3338. [PubMed]
6. Andersen JK. Oxidative stress in neurodegeneration: cause or consequence? Nat Med. 2004;10(Suppl):S18–S25. [PubMed]
7. Angelini G. Gardella S. Ardy M. Ciriolo MR. Filomeni G. Di Trapani G. Clarke F. Sitia R. Rubartelli A. Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. Proc Natl Acad Sci USA. 2002;99:1491–1496. [PubMed]
8. Banerjee R. Vitvitsky V. Garg SK. The undertow of sulfur metabolism on glutamatergic neurotransmission. Trends Biochem Sci. 2008;33:413–419. [PubMed]
9. Banerjee R. Zou CG. Redox regulation and reaction mechanism of human cystathionine-beta-synthase: a PLP-dependent hemesensor protein. Arch Biochem Biophys. 2005;433:144–156. [PubMed]
10. Beatty PW. Reed DJ. Involvement of the cystathionine pathway in the biosynthesis of glutathione by isolated rat hepatocytes. Arch Biochem Biophys. 1980;204:80–87. [PubMed]
11. Behl C. Davis JB. Lesley R. Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell. 1994;77:817–827. [PubMed]
12. Butterfield DA. Drake J. Pocernich C. Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med. 2001;7:548–554. [PubMed]
13. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging. 1997;18:S1–S2. [PubMed]
14. Dringen R. Gutterer JM. Hirrlinger J. Glutathione metabolism in brain metabolic interaction between astrocytes and neurons in the defense against reactive oxygen species. Eur J Biochem. 2000;267:4912–4916. [PubMed]
15. Dringen R. Pfeiffer B. Hamprecht B. Synthesis of the antioxidant glutathione in neurons: supply by astrocytes of CysGly as precursor for neuronal glutathione. J Neurosci. 1999;19:562–569. [PubMed]
16. Dumont M. Wille E. Stack C. Calingasan NY. Beal MF. Lin MT. Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease. FASEB J. 2009;23:2459–2466. [PubMed]
17. Eto K. Asada T. Arima K. Makifuchi T. Kimura H. Brain hydrogen sulfide is severely decreased in Alzheimer's disease. Biochem Biophys Res Commun. 2002;293:1485–1488. [PubMed]
18. Finkelstein JD. Kyle WE. Martin JL. Pick AM. Activation of cystathionine synthase by adenosylmethionine and adenosylethionine. Biochem Biophys Res Commun. 1975;66:81–87. [PubMed]
19. Garg S. Vitvitsky V. Gendelman HE. Banerjee R. Monocyte differentiation, activation, and mycobacterial killing are linked to transsulfuration-dependent redox metabolism. J Biol Chem. 2006;281:38712–38720. [PubMed]
20. Garg SK. Banerjee R. Kipnis J. Neuroprotective immunity: T cell-derived glutamate endows astrocytes with a neuroprotective phenotype. J Immunol. 2008;180:3866–3873. [PubMed]
21. Garg SK. Kipnis J. Banerjee R. IFN-gamma and IL-4 differentially shape metabolic responses and neuroprotective phenotype of astrocytes*. J Neurochem. 2009;108:1155–1166. [PubMed]
22. Go YM. Jones DP. Redox compartmentalization in eukaryotic cells. Biochim Biophys Acta. 2008;1780:1273–1290. [PMC free article] [PubMed]
23. Gsell W. Conrad R. Hickethier M. Sofic E. Frolich L. Wichart I. Jellinger K. Moll G. Ransmayr G. Beckmann H, et al. Decreased catalase activity but unchanged superoxide dismutase activity in brains of patients with dementia of Alzheimer type. J Neurochem. 1995;64:1216–1223. [PubMed]
24. Gunasingh MJ. Philip JE. Ashok BS. Kirubagaran R. Jebaraj WC. Davis GD. Vignesh S. Dhandayuthapani S. Jayakumar R. Melatonin prevents amyloid protofibrillar induced oxidative imbalance and biogenic amine catabolism. Life Sci. 2008;83:96–102. [PubMed]
25. Habib LK. Lee MT. Yang J. Inhibitors of catalase-amyloid interactions protect cells from beta-amyloid-induced oxidative stress and toxicity. J Biol Chem. 2010;285:38933–38943. [PubMed]
26. Hattori N. Kitagawa K. Higashida T. Yagyu K. Shimohama S. Wataya T. Perry G. Smith MA. Inagaki C. CI-ATPase and Na+/K(+)-ATPase activities in Alzheimer's disease brains. Neurosci Lett. 1998;254:141–144. [PubMed]
27. Hernandez-Guillamon M. Delgado P. Ortega L. Pares M. Rosell A. Garcia-Bonilla L. Fernandez-Cadenas I. Borrell-Pages M. Boada M. Montaner J. Neuronal TIMP-1 release accompanies astrocytic MMP-9 secretion and enhances astrocyte proliferation induced by beta-amyloid 25–35 fragment. J Neurosci Res. 2009;87:2115–2125. [PubMed]
28. Kharrazi H. Vaisi-Raygani A. Rahimi Z. Tavilani H. Aminian M. Pourmotabbed T. Association between enzymatic and non-enzymatic antioxidant defense mechanism with apolipoprotein E genotypes in Alzheimer disease. Clin Biochem. 2008;41:932–936. [PubMed]
29. Lauderback CM. Hackett JM. Huang FF. Keller JN. Szweda LI. Markesbery WR. Butterfield DA. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42. J Neurochem. 2001;78:413–416. [PubMed]
30. Manelli AM. Puttfarcken PS. beta-Amyloid-induced toxicity in rat hippocampal cells: in vitro evidence for the involvement of free radicals. Brain Res Bull. 1995;38:569–576. [PubMed]
31. Marcus DL. Thomas C. Rodriguez C. Simberkoff K. Tsai JS. Strafaci JA. Freedman ML. Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. Exp Neurol. 1998;150:40–44. [PubMed]
32. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature. 2004;430:631–639. [PMC free article] [PubMed]
33. Moriarty-Craige SE. Jones DP. Extracellular thiols and thiol/disulfide redox in metabolism. Annu Rev Nutr. 2004;24:481–509. [PubMed]
34. Morrison LD. Smith DD. Kish SJ. Brain S-adenosylmethionine levels are severely decreased in Alzheimer's disease. J Neurochem. 1996;67:1328–1331. [PubMed]
35. Mosharov E. Cranford MR. Banerjee R. The quantitatively important relationship between homocysteine metabolism and glutathione synthesis by the transsulfuration pathway and its regulation by redox changes. Biochemistry. 2000;39:13005–13011. [PubMed]
36. Olney JW. Zorumski C. Price MT. Labruyere J. L-cysteine, a bicarbonate-sensitive endogenous excitotoxin. Science. 1990;248:596–599. [PubMed]
37. Pike CJ. Burdick D. Walencewicz AJ. Glabe CG. Cotman CW. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci. 1993;13:1676–1687. [PubMed]
38. Pike CJ. Cummings BJ. Monzavi R. Cotman CW. Beta-amyloid-induced changes in cultured astrocytes parallel reactive astrocytosis associated with senile plaques in Alzheimer's disease. Neuroscience. 1994;63:517–531. [PubMed]
39. Prudova A. Bauman Z. Braun A. Vitvitsky V. Lu SC. Banerjee R. S-adenosylmethionine stabilizes cystathionine beta-synthase and modulates redox capacity. Proc Natl Acad Sci USA. 2006;103:6489–6494. [PubMed]
40. Ramassamy C. Averill D. Beffert U. Bastianetto S. Theroux L. Lussier-Cacan S. Cohn JS. Christen Y. Davignon J. Quirion R. Poirier J. Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. Free Radic Biol Med. 1999;27:544–553. [PubMed]
41. Rival T. Page RM. Chandraratna DS. Sendall TJ. Ryder E. Liu B. Lewis H. Rosahl T. Hider R. Camargo LM. Shearman MS. Crowther DC. Lomas DA. Fenton chemistry and oxidative stress mediate the toxicity of the beta-amyloid peptide in a Drosophila model of Alzheimer's disease. Eur J Neurosci. 2009;29:1335–1347. [PMC free article] [PubMed]
42. Robert K. Vialard F. Thiery E. Toyama K. Sinet PM. Janel N. London J. Expression of the cystathionine beta synthase (CBS) gene during mouse development and immunolocalization in adult brain. J Histochem Cytochem. 2003;51:363–371. [PubMed]
43. Schafer FQ. Buettner GR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med. 2001;30:1191–1212. [PubMed]
44. Singh S. Madzelan P. Stasser J. Weeks CL. Becker D. Spiro TG. Penner-Hahn J. Banerjee R. Modulation of the heme electronic structure and cystathionine beta-synthase activity by second coordination sphere ligands: the role of heme ligand switching in redox regulation. J Inorg Biochem. 2009;103:689–697. [PMC free article] [PubMed]
45. Stewart VC. Stone R. Gegg ME. Sharpe MA. Hurst RD. Clark JB. Heales SJ. Preservation of extracellular glutathione by an astrocyte derived factor with properties comparable to extracellular superoxide dismutase. J Neurochem. 2002;83:984–991. [PubMed]
46. Vitvitsky V. Dayal S. Stabler S. Zhou Y. Wang H. Lentz SR. Banerjee R. Perturbations in homocysteine-linked redox homeostasis in a murine model for hyperhomocysteinemia. Am J Physiol Regul Integr Comp Physiol. 2004;287:R39–R46. [PubMed]
47. Vitvitsky V. Thomas M. Ghorpade A. Gendelman HE. Banerjee R. A functional transsulfuration pathway in the brain links to glutathione homeostasis. J Biol Chem. 2006;281:35785–35793. [PubMed]
48. Vural H. Demirin H. Kara Y. Eren I. Delibas N. Alterations of plasma magnesium, copper, zinc, iron and selenium concentrations and some related erythrocyte antioxidant enzyme activities in patients with Alzheimer's disease. J Trace Elem Med Biol. 2010;24:169–173. [PubMed]
49. Yan Z. Garg SK. Kipnis J. Banerjee R. Extracellular redox modulation by regulatory T cells. Nat Chem Biol. 2009;5:721–723. [PMC free article] [PubMed]

Articles from Antioxidants & Redox Signaling are provided here courtesy of Mary Ann Liebert, Inc.